Image pharmaphorum Editor News Sanofi stockpiles drugs in case of no-deal Brexit Fears of border delays and complications in a post-Brexit UK have led to the French pharmaceutical company increasing its contingency stockpiles by four weeks to enable a 14-week supply of News Roche’s MS drug Ocrevus earns blockbuster status a year afte... Roche’s multiple sclerosis (MS) drug Ocrevus (ocrelizumab) has claimed blockbuster status just one year after it was launched. News FDA refuses to approve Insys opioid painkiller The US regulators have rejected Insys Therapeutics' opioid-based painkiller because of concerns about its safety. News Indivior's once-monthly schizophrenia injection gets US gree... Regulators authorities in the US have approved Indivior’s long-acting injectable treatment for adults with schizophrenia. Load more results
News Sanofi stockpiles drugs in case of no-deal Brexit Fears of border delays and complications in a post-Brexit UK have led to the French pharmaceutical company increasing its contingency stockpiles by four weeks to enable a 14-week supply of
News Roche’s MS drug Ocrevus earns blockbuster status a year afte... Roche’s multiple sclerosis (MS) drug Ocrevus (ocrelizumab) has claimed blockbuster status just one year after it was launched.
News FDA refuses to approve Insys opioid painkiller The US regulators have rejected Insys Therapeutics' opioid-based painkiller because of concerns about its safety.
News Indivior's once-monthly schizophrenia injection gets US gree... Regulators authorities in the US have approved Indivior’s long-acting injectable treatment for adults with schizophrenia.
News After CagriSema blow, Novo reveals data for obesity 'triple' Novo Nordisk's triple-action obesity therapy UBT251, licensed in a $2bn deal last year, achieved almost 20% weight loss in a mid-stage trial.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
